
Core Elements of the new GHSS (2022-2030)







Dr 'Funmi Lesi, Global Hepatitis Programme Global HIV, Hepatitis and STIs Programmes World Health Organization HQ, Geneva, Switzerland

The new GHSS (2022-2030) builds on the first ever global World Health Organization health sector strategies for Viral Hepatitis (2016-2021)









Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016–2021: actions for impact. Geneva: World Health Organization; 2021

World Health World Health Organization

Why post 2021 Global Health Sector Strategies?



- Hepatitis remains a high priority for countries
- New epidemiological trend data, including regional variations
- Advances in science, technology and innovation
- Advances in community-based service delivery and differentiated care
- COVID-19 context
- Strengthening of linkages and integration
- Shifts in donor funding especially for middle-income countries
- Alignment with WHO GPW13
- Inclusion of 2025 "mid point" and 2030 targets

Vision, goals and strategic directions



https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies/developing-ghss-2022-2030

Proposed strategic framework:

End epidemics and advance universal health coverage, primary health care and health security A common vision **Impact** indicators **Disease goals** End AIDS and the epidemics of viral hepatitis and sexually transmitted infections by 2030 and targets HIV **Viral hepatitis** Sexually transmitted **Strategic** Strategy infections strategy Strategy directions 1. Deliver high-quality, evidence-based, people-centred, services with 2. Optimize systems, sectors and partnerships for impact shared and 3. Generate and use data to drive decisions for action disease-**Shared** specific 4. Engage empowered communities and civil society actions Per disease area 5. Foster innovations for impact **Drivers of** - Gender, equity, and human rights - Financing progress - Leadership and partnerships

Innovations to accelerate action



Viral Hepatitis



New viral hepatitis diagnostics technologies and testing approaches - improve diagnostics technologies &testing approaches for simplified & accurate HBV &HCV inc self testing & self care approaches



Optimized antivirals for hepatitis B and C virus. Support research on optimal doses & formulations of antivirals for HBV &HCV that minimize toxicity, drug-drug interactions and reduce costs; **ensure safer antivirals for pregnant and lactating women**



New viral hepatitis vaccines. Promote HCV & HEV virus vaccine agenda by promoting investments and visibility in efforts to secure a viable HCV vaccine, inc through strengthened collaboration with R&D partnerships, the private sector and communities.



Hepatitis B virus cure. Promote investments and visibility in efforts to secure a viable HBV cure through strengthened collaboration with R&D partnerships, the private sector and communities.



<u>Partnerships for innovation</u>. Optimize the potential for innovation through market analyses and strengthening research- and development-based partnerships, including strengthened engagement with the private sector.



Proposed impact indicators and targets for hepatitis




Disease area	Impact indicator	Baseline 2020 ^b	2025 target	2030 target
Viral hepatitis Proposed impact indicators and targets Viral hepatitis	Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years old	0.94%	0.5%	0.1%
	Number of new hepatitis B infections per year	1.5 million new cases	850 000 new cases	170 000 new cases
		20 per 100 000	11 per 100 000	2 per 100 000
	Number of new hepatitis C infections per year	1.575 million new cases	1 million new cases	350 000 new cases
		20 per 100 000	13 per 100 000	5 per 100 000
	Number of new hepatitis C infections among persons who inject drugs per year	8 per 100	3 per 100	2 per 100
	Number of deaths due to hepatitis B per year	820 000 deaths	530 000 deaths	310 000 deaths
		10 per 100 000	7 per 100 000	4 per 100 000
	Number of deaths due to hepatitis C per year	290 000 deaths	240 000 deaths	140 000 deaths
		5 per 100 000	3 per 100 000	2 per 100 000

WHO website



Key stages of the **strategies' development process**, including **reports of the regional and virtual consultation**, and the **final full draft strategy and table outlining WHO Secretariat response is** available online.



New Directions - Updating WHO hepatitis guidelines World Health 2021-2022

HCV treatment:


- Simplified service delivery
- Reconciling paediatric and adult DAA regimens
- Re-treatment approaches and regimens

Testing: ongoing UNITAID funded portfolio

- Use of PoC viral load
- Reflex viral load
- HCV Self-testing
- Dried Blood spots

HBV treatment:

- Simplifying service delivery
- Expanding criteria for treatment (lower APRI score and HBV DNA threshold)
- TAF vs. TDF
- Delta virus testing and treatment





WHO

20, Avenue Appia 1211 Geneva

Switzerland

Thank you